---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000076"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:44:38.581256+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development

## Summary
- SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).
- U.S. TD market reached $3.7B in 2024; projected to grow to $5.4B by 2030.
- Fewer than 30% of U.S. TD patients are diagnosed; less than half receive treatment.
- Serina plans to explore POZ-VMAT2i for Huntington's chorea as a secondary indication.
- CEO Steve Ledger to present at BTIG Virtual Biotechnology Conference on July 29, 2025.

## SEC filing metadata
- accession: 0001708599-25-000076
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000076/0001708599-25-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000076/ser-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000076
- JSON: https://secwatch.observer/filing/0001708599-25-000076.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.